Effect of Basal Septal Hypertrophy on TAVR Outcomes: Evidence From a Large Cohort Study
Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1267-1276
DOI: 10.1002/ccd.70462 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 11.01.2026. Verfasst von Ziad Arow und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinique Pasteur, Toulouse, France. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Aortic Valve, Transcatheter Aortic Valve Replacement, Heart Septum. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Basal septal hypertrophy (BSH) is commonly encountered in elderly patients undergoing transcatheter aortic valve replacement (TAVR). However, its impact on periprocedural and procedural outcomes remains unclear.
Aims
The aim of this study was to evaluate the effect of BSH on periprocedural and postprocedural outcomes in patients undergoing TAVR.
Methods
This study included patients with severe aortic stenosis (AS) who underwent TAVR using either balloon‐expandable (BEVs) or self‐expanding valves (SEVs). The primary endpoint was to compare periprocedural interventions and procedural outcomes. Secondary endpoints included subgroup analyses by device generation (new vs. old), valve type (BEVs vs. SEVs), severity of septal hypertrophy, and across study periods.
Results
A total of 3261 TAVR patients were included: 1050 had a BSH ≥ 15 mm (HS+ group) and 2211 had a septal thickness < 15 mm (HS– group). Patients in the HS+ group had higher rates of post‐dilatation (25% vs. 21%, p = 0.008), moderate or greater paravalvular leak (PVL) on angiography (2.4% vs. 0.8%, p < 0.001) and echocardiography (5% vs. 3.4%, p = 0.033), and permanent pacemaker (PPM) implantation (18% vs. 14%, p = 0.008). Conversely, HS− patients more often required valve repositioning and a second valve. In subgroup analyses stratified by device generation, the influence of BSH appeared broadly consistent across platforms. Additional Subgroup analysis showed particularly higher rates of post‐dilatation, moderate or greater PVL, and PPM implantation in the SEV HS+ group, whereas mild septal thickening (12–15 mm) had no significant impact compared with marked hypertrophy (≥ 15 mm).
Conclusion
In this large cohort of TAVR patients, BSH (≥ 15 mm) was associated with higher rates of post‐dilatation, PVL, and PPM implantation, particularly among those receiving SEVs, while mild septal thickening had no significant impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinique Pasteur, Toulouse, France.
- Cardiology Department, Meir Medical Center, Israel.
ORCID-Profile: Omar Oliva, Juri Iwata, Chiara De Biase
Zitieren
APA
Arow, Z., Oliva, O., Iwata, J., Masumoto, A., Bonfils, L., Lepage, L., Assali, A., De Biase, C., Dumonteil, N., & Tchetche, D. (2026). Effect of Basal Septal Hypertrophy on TAVR Outcomes: Evidence From a Large Cohort Study. Catheterization and Cardiovascular Interventions, 107(4), 1267-1276. https://doi.org/10.1002/ccd.70462
Vancouver
Arow Z, Oliva O, Iwata J, Masumoto A, Bonfils L, Lepage L, et al. Effect of Basal Septal Hypertrophy on TAVR Outcomes: Evidence From a Large Cohort Study. Catheterization and Cardiovascular Interventions. 2026;107(4):1267-1276. doi:10.1002/ccd.70462
BibTeX
@article{Arow2026,
author = {Arow, Ziad and Oliva, Omar and Iwata, Juri and Masumoto, Akiko and Bonfils, Laurent and Lepage, Laurent and Assali, Abid and De Biase, Chiara and Dumonteil, Nicolas and Tchetche, Didier},
title = {Effect of Basal Septal Hypertrophy on TAVR Outcomes: Evidence From a Large Cohort Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {4},
pages = {1267--1276},
doi = {10.1002/ccd.70462}
}
EUVIMED